Focus on Inflammatory Disease

Innate lymphoid cells in the initiation, regulation and resolution of inflammation

Journal name:
Nature Medicine
Volume:
21,
Pages:
698–708
Year published:
DOI:
doi:10.1038/nm.3892
Received
Accepted
Published online

Abstract

A previously unappreciated cell type of the innate immune system, termed innate lymphoid cells (ILCs), has been characterized in mice and humans and found to influence the induction, regulation and resolution of inflammation. ILCs have an important role in these processes in mouse models of infection, inflammation and tissue repair. Further, disease-association studies in defined patient populations have identified significant alterations in ILC responses, suggesting a potential role for these cell populations in human health and disease. In this review we discuss the emerging family of ILCs, the role of ILCs in inflammation, and how current or novel therapeutic strategies could be used to selectively modulate ILC responses and limit chronic inflammatory diseases.

At a glance

Figures

  1. Development and heterogeneity of the ILC family.
    Figure 1: Development and heterogeneity of the ILC family.

    ILCs develop from distinct progenitors in the fetal liver or bone marrow. All ILCs develop from CLPs, which can differentiate into NKps or CHILPs. CHILPs can further differentiate into LTi cells through α4β7 integrin-expressing intermediate populations, or into other ILC populations through differentiation to a PLZF-dependent ILCp. Further sequential engagement of transcription factors, cytokines and microbial signals is critical for the development of three distinct groups of mature ILCs. ILC1s express T-bet, are responsive to IL-12, and produce IFN-γ. ILC2s highly express GATA3; are responsive to IL-25, IL-33 and TSLP; and produce IL-4, IL-5, IL-9, IL-13 and amphiregulin. ILC3s express RORγt, are responsive to IL-1β and IL-23, and produce IL-17 and/or IL-22.

  2. ILCs promote acute inflammation and innate immunity to pathogens.
    Figure 2: ILCs promote acute inflammation and innate immunity to pathogens.

    ILCs promote innate immune responses to a number of pathogens in the intestine. (a) ILC1s promote innate immunity to intracellular pathogens, such as T. gondii, by producing TNF and IFN-γ in response to DC-derived IL-12, and they subsequently promote recruitment of inflammatory myeloid cells. (b) After infection with the helminth parasites N. brasiliensis or T. muris, ILC2s produce IL-13 in response to epithelial cell–derived IL-25, IL-33 and TSLP, which increases smooth muscle contractility and mucus production from goblet cells. (c) ILC3s produce IL-17 and IL-22 in response to DC-derived IL-23 and IL-1β, which promotes innate immunity to fungi and extracellular bacteria, such as C. rodentium and C. albicans. IL-17 and IL-22 promote neutrophil recruitment to the intestine and the production of antimicrobial peptides from IECs.

  3. ILC2s and ILC3s promote the resolution of inflammation and tissue repair.
    Figure 3: ILC2s and ILC3s promote the resolution of inflammation and tissue repair.

    (a) After viral infection in the lung, airway epithelial cells are damaged and, in conjunction with resident myeloid cell populations, produce IL-33. ILC2s respond to IL-33 and produce amphiregulin, which promotes repair of the airway epithelium. (b) In lymphoid tissues, such as the spleen and thymus, stromal cell damage induced by viral infection or irradiation results in increased numbers of ILC3s and increased cytokine production, in response to DC-derived IL-23. ILC3s directly promote restoration of stromal cell compartments through production of LTα1β2 and IL-22, which increase the proliferation and survival of tissue resident stromal cells. (c) In the intestine, ILC3 responses can be limited by a regulatory loop whereby commensal bacteria induce IEC expression of IL-25, which acts on DCs to limit ILC3 cytokine responses in a contact-dependent manner. In contrast, upon chemical-, infection- or irradiation-induced damage of the intestine, ILC3s are activated by DC-derived IL-1β, IL-23, TL1A and RA. Activation of ILC3s induces IL-22 production that directly promotes mucus production and epithelial cell repair, in part by acting directly on intestinal stem cells or progenitors.

  4. ILCs can promote chronic inflammation.
    Figure 4: ILCs can promote chronic inflammation.

    (a) In response to infection or allergen exposure, ILC2 responses are elicited in the lung (and skin) by epithelial cell– and myeloid cell–derived IL-25, IL-33 and TSLP. Further, ILC2 responses can be enhanced by basophil-derived IL-4 or mast cell-derived PGD2. Activated ILC2s can subsequently promote chronic inflammation via IL-5–dependent eosinophil recruitment, IL-13–mediated contraction of smooth muscle cells, collagen deposition, and AAMac differentiation, or by MHCII-mediated enhancement of TH2 cell responses, resulting in allergy and fibrosis. (b) In patients with psoriasis and in mouse models of skin inflammation, ILC3 responses are increased, which can occur in response to DC-derived IL-23. ILC3s largely promote skin inflammation through production of IL-22 and IL-17. Further, ILC3s are increased in the bronchoalveolar lavage fluid of patients with asthma and in mouse models of obesity-induced asthma. In mice this occurs through activation of the NLRP3 inflammasome and macrophage (Mφ) production of IL-1β. IL-1β activates ILC3s to produce IL-17, which directly promotes airway inflammation and hyper-responsiveness. (c) In the intestine ILC3s can promote IL-22–dependent tumor growth, which is in part dependent upon DC-derived IL-23. Further, ILC3s can mediate tissue inflammation in the intestine in response to DC-derived IL-23 and IL-12. This may occur through production of IL-17 by ILC3s, production of IFN-γ following loss of RORγt in ILC3s and differentiation to ex-ILC3s, or direct activation of tissue-resident ILC1s.

  5. ILCs can prevent or limit chronic inflammation.
    Figure 5: ILCs can prevent or limit chronic inflammation.

    (a) In the intestine, ILC2s respond to epithelial cell-derived IL-33, IL-25 and vasoactive intestinal peptide (VIP) to promote IL-5– and IL-13–dependent recruitment of eosinophils and differentiation of AAMacs. This process also occurs in adipose tissue, although the sources of IL-25 or IL-33 are less well defined. Differentiation of AAMacs or direct stimulation of adipocytes with IL-13 or methionine-enkephalin peptides (Met-enk) can promote metabolic homeostasis through a process known as beiging in the adipocytes. (b) ILC3s can limit chronic inflammation by regulating innate and adaptive immune responses in the intestine. ILC3 responses are induced in response to myeloid cell– and DC-derived IL-1β and IL-23 after recognition of pathogenic or commensal microbes. Production of ILC3-derived LTα1β2 or LTα3 can promote IgA production by B cells indirectly by modulating stromal cell or DC responses. Production of ILC3-derived GM-CSF can influence myeloid cell homeostasis to subsequently promote Treg cell responses and tolerance to food antigens. ILC3-intrinsic MHCII can directly kill commensal bacteria-specific CD4+ T cells with the potential to cause intestinal inflammation. Production of IL-22 by ILC3s can promote antimicrobial peptide production by IECs to limit colonization with commensal bacteria, such as segmented filamentous bacteria (SFB), or it can regulate the anatomical localization of lymphoid tissue resident commensal bacteria. Further, ILC3-derived IL-22 can induce fucosylation of IECs to promote colonization with beneficial bacteria.

References

  1. Grivennikov, S.I., Greten, F.R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883899 (2010).
  2. Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428435 (2008).
  3. Spits, H. et al. Innate lymphoid cells–a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145149 (2013).
  4. Walker, J.A., Barlow, J.L. & McKenzie, A.N. Innate lymphoid cells–how did we miss them? Nat. Rev. Immunol. 13, 7587 (2013).
  5. Sonnenberg, G.F., Mjösberg, J., Spits, H. & Artis, D. SnapShot: innate lymphoid cells. Immunity 39, 622 (2013).
  6. Sonnenberg, G.F. & Artis, D. Innate lymphoid cell interactions with microbiota: implications for intestinal health and disease. Immunity 37, 601610 (2012).
  7. Zheng, Y. et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14, 282289 (2008).
  8. Sonnenberg, G.F., Fouser, L.A. & Artis, D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12, 383390 (2011).
  9. Aujla, S.J. et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat. Med. 14, 275281 (2008).
  10. Ouyang, W., Kolls, J.K. & Zheng, Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28, 454467 (2008).
  11. Harrington, L.E., Mangan, P.R. & Weaver, C.T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 18, 349356 (2006).
  12. Ahern, P.P., Izcue, A., Maloy, K.J. & Powrie, F. The interleukin-23 axis in intestinal inflammation. Immunol. Rev. 226, 147159 (2008).
  13. Fallon, P.G. et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J. Exp. Med. 203, 11051116 (2006).
  14. Saenz, S.A., Taylor, B.C. & Artis, D. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol. Rev. 226, 172190 (2008).
  15. Liew, F.Y., Pitman, N.I. & McInnes, I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103110 (2010).
  16. Liu, Y.J. et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu. Rev. Immunol. 25, 193219 (2007).
  17. Fort, M.M. et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15, 985995 (2001).
  18. Kiessling, R., Klein, E., Pross, H. & Wigzell, H. “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur. J. Immunol. 5, 117121 (1975).
  19. Pross, H.F. & Jondal, M. Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes. Clin. Exp. Immunol. 21, 226235 (1975).
  20. Mebius, R.E., Rennert, P. & Weissman, I.L. Developing lymph nodes collect CD4+CD3 LTβ+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 7, 493504 (1997).
  21. Sonnenberg, G.F., Monticelli, L.A., Elloso, M.M., Fouser, L.A. & Artis, D. CD4+ lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 34, 122134 (2011).
  22. Cella, M. et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457, 722725 (2009).
  23. Satoh-Takayama, N. et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 29, 958970 (2008).
  24. Buonocore, S. et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464, 13711375 (2010).
  25. Sawa, S. et al. Lineage relationship analysis of RORγt+ innate lymphoid cells. Science 330, 665669 (2010).
  26. Cupedo, T. et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+CD127+ natural killer-like cells. Nat. Immunol. 10, 6674 (2009).
  27. Crellin, N.K. et al. Regulation of cytokine secretion in human CD127+ LTi-like innate lymphoid cells by Toll-like receptor 2. Immunity 33, 752764 (2010).
  28. Sanos, S.L. et al. RORγt and commensal microflora are required for the differentiation of mucosal interleukin 22–producing NKp46+ cells. Nat. Immunol. 10, 8391 (2009).
  29. Moro, K. et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells. Nature 463, 540544 (2010).
  30. Price, A.E. et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc. Natl. Acad. Sci. USA 107, 1148911494 (2010).
  31. Monticelli, L.A. et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12, 10451054 (2011).
  32. Mjösberg, J.M. et al. Human IL-25– and IL-33–responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat. Immunol. 12, 10551062 (2011).
  33. Neill, D.R. et al. Nuocytes represent a new innate effector leukocyte that mediates type 2 immunity. Nature 464, 13671370 (2010).
  34. Cherrier, M., Sawa, S. & Eberl, G. Notch, Id2, and RORγt sequentially orchestrate the fetal development of lymphoid tissue inducer cells. J. Exp. Med. 209, 729740 (2012).
  35. Constantinides, M.G., McDonald, B.D., Verhoef, P.A. & Bendelac, A. A committed precursor to innate lymphoid cells. Nature 508, 397401 (2014).
  36. Klose, C.S. et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 157, 340356 (2014).
  37. Diefenbach, A., Colonna, M. & Koyasu, S. Development, differentiation, and diversity of innate lymphoid cells. Immunity 41, 354365 (2014).
  38. Artis, D. & Spits, H. The biology of innate lymphoid cells. Nature 517, 293301 (2015).
  39. Xu, W. et al. NFIL3 orchestrates the emergence of common helper innate lymphoid cell precursors. Cell Rep. 10, 20432054 (2015).
  40. Geiger, T.L. et al. Nfil3 is crucial for development of innate lymphoid cells and host protection against intestinal pathogens. J. Exp. Med. 211, 17231731 (2014).
  41. Yu, X. et al. The basic leucine zipper transcription factor NFIL3 directs the development of a common innate lymphoid cell precursor. elife http://dx.doi.org/10.7554/eLife.0440 (2014).
  42. Seillet, C. et al. Nfil3 is required for the development of all innate lymphoid cell subsets. J. Exp. Med. 211, 17331740 (2014).
  43. Kobayashi, T. et al. NFIL3-deficient mice develop microbiota-dependent, IL-12/23-driven spontaneous colitis. J. Immunol. 192, 19181927 (2014).
  44. Seehus, C.R. et al. The development of innate lymphoid cells requires TOX-dependent generation of a common innate lymphoid cell progenitor. Nat. Immunol. 16, 599608 (2015).
  45. Aliahmad, P., de la Torre, B. & Kaye, J. Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat. Immunol. 11, 945952 (2010).
  46. Yang, Q. et al. T cell factor 1 is required for group 2 innate lymphoid cell generation. Immunity 38, 694704 (2013).
  47. Mielke, L.A. et al. TCF-1 controls ILC2 and NKp46+RORγt+ innate lymphocyte differentiation and protection in intestinal inflammation. J. Immunol. 191, 43834391 (2013).
  48. Yagi, R. et al. The transcription factor GATA3 is critical for the development of all IL-7Rα-expressing innate lymphoid cells. Immunity 40, 378388 (2014).
  49. Serafini, N. et al. Gata3 drives development of RORγt+ group 3 innate lymphoid cells. J. Exp. Med. 211, 199208 (2014).
  50. Montaldo, E. et al. Human RORγt+CD34+ cells are lineage-specified progenitors of group 3 RORγt+ innate lymphoid cells. Immunity 41, 9881000 (2014).
  51. Bernink, J.H. et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat. Immunol. 14, 221229 (2013).
  52. Fuchs, A. et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells. Immunity 38, 769781 (2013).
  53. Hoyler, T. et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 37, 634648 (2012).
  54. Mjösberg, J. et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 37, 649659 (2012).
  55. Klein Wolterink, R.G. et al. Essential, dose-dependent role for the transcription factor Gata3 in the development of IL-5+ and IL-13+ type 2 innate lymphoid cells. Proc. Natl. Acad. Sci. USA 110, 1024010245 (2013).
  56. Furusawa, J. et al. Critical role of p38 and GATA3 in natural helper cell function. J. Immunol. 191, 18181826 (2013).
  57. Wong, S.H. et al. Transcription factor RORα is critical for nuocyte development. Nat. Immunol. 13, 229236 (2012).
  58. Halim, T.Y. et al. Retinoic-acid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation. Immunity 37, 463474 (2012).
  59. Robinette, M.L. et al. Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat. Immunol. 16, 306317 (2015).
  60. Spooner, C.J. et al. Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. Nat. Immunol. 14, 12291236 (2013).
  61. Walker, J.A. et al. Bcl11b is essential for group 2 innate lymphoid cell development. J. Exp. Med. (in the press, 2015).
  62. Yu, Y. et al. The transcription factor Bcl11b is specifically expressed in group 2 innate lymphoid cells and is essential for their development. J. Exp. Med. (in the press, 2015).
  63. Kim, B.S. et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci. Transl. Med. 5, 70ra116 (2013).
  64. Molofsky, A.B. et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J. Exp. Med. 210, 535549 (2013).
  65. Hams, E., Locksley, R.M., McKenzie, A.N. & Fallon, P.G. Cutting edge: IL-25 elicits innate lymphoid type 2 and type II NKT cells that regulate obesity in mice. J. Immunol. 191, 53495353 (2013).
  66. Brestoff, J.R. et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519, 242246 (2015).
  67. Eberl, G. et al. An essential function for the nuclear receptor RORγ(t) in the generation of fetal lymphoid tissue inducer cells. Nat. Immunol. 5, 6473 (2004).
  68. Klose, C.S. et al. A T-bet gradient controls the fate and function of CCR6-RORγt+ innate lymphoid cells. Nature 494, 261265 (2013).
  69. Kiss, E.A. et al. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science 334, 15611565 (2011).
  70. Lee, J.S. et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat. Immunol. 13, 144151 (2012).
  71. Qiu, J. et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 36, 92104 (2012).
  72. Vonarbourg, C. et al. Regulated expression of nuclear receptor RORγt confers distinct functional fates to NK cell receptor-expressing RORγt+ innate lymphocytes. Immunity 33, 736751 (2010).
  73. Bouskra, D. et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 456, 507510 (2008).
  74. Mackley, E.C. et al. CCR7-dependent trafficking of RORγ+ ILCs creates a unique microenvironment within mucosal draining lymph nodes. Nat. Commun. 6, 5862 (2015).
  75. Teunissen, M.B. et al. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR+ ILC3 in lesional skin and blood of psoriasis patients. J. Invest. Dermatol. 134, 23512360 (2014).
  76. Powell, N. et al. The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. Immunity 37, 674684 (2012).
  77. Huang, Y. et al. IL-25-responsive, lineage-negative KLRG1hi cells are multipotential 'inflammatory' type 2 innate lymphoid cells. Nat. Immunol. 16, 161169 (2015).
  78. Sun, J.C. & Lanier, L.L. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat. Rev. Immunol. 11, 645657 (2011).
  79. Maizels, R.M., Hewitson, J.P. & Smith, K.A. Susceptibility and immunity to helminth parasites. Curr. Opin. Immunol. 24, 459466 (2012).
  80. Artis, D. et al. RELMβ/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract. Proc. Natl. Acad. Sci. USA 101, 1359613600 (2004).
  81. Spencer, S.P. et al. Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity. Science 343, 432437 (2014).
  82. Sugimoto, K. et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118, 534544 (2008).
  83. Pham, T.A. et al. Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. Cell Host Microbe 16, 504516 (2014).
  84. Goto, Y. et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science 345, 1254009 (2014).
  85. Pickard, J.M. et al. Rapid fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness. Nature 514, 638641 (2014).
  86. Gladiator, A., Wangler, N., Trautwein-Weidner, K. & LeibundGut-Landmann, S. Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. J. Immunol. 190, 521525 (2013).
  87. Sonnenberg, G.F. et al. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J. Exp. Med. 207, 12931305 (2010).
  88. Deshmukh, H.S. et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat. Med. 20, 524530 (2014).
  89. Turner, J.E. et al. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J. Exp. Med. 210, 29512965 (2013).
  90. Salimi, M. et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J. Exp. Med. 210, 29392950 (2013).
  91. Scandella, E. et al. Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone. Nat. Immunol. 9, 667675 (2008).
  92. Dudakov, J.A. et al. Interleukin-22 drives endogenous thymic regeneration in mice. Science 336, 9195 (2012).
  93. Matsumoto, A. et al. IL-22-producing RORgammat-dependent innate lymphoid cells play a novel protective role in murine acute hepatitis. PLoS ONE 8, e62853 (2013).
  94. Kumar, P., Thakar, M.S., Ouyang, W. & Malarkannan, S. IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol. 6, 6982 (2013).
  95. Takayama, T. et al. Imbalance of NKp44+NKp46 and NKp44NKp46+ natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology 139, 882892 (2010).
  96. Ciccia, F. et al. Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum. 64, 18691878 (2012).
  97. Sawa, S. et al. RORγt+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat. Immunol. 12, 320326 (2011).
  98. Hanash, A.M. et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 37, 339350 (2012).
  99. Mielke, L.A. et al. Retinoic acid expression associates with enhanced IL-22 production by γδ T cells and innate lymphoid cells and attenuation of intestinal inflammation. J. Exp. Med. 210, 11171124 (2013).
  100. Munneke, J.M. et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood 124, 812821 (2014).
  101. Zaph, C. et al. Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J. Exp. Med. 205, 21912198 (2008).
  102. Longman, R.S. et al. CX(3)CR1+ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J. Exp. Med. 211, 15711583 (2014).
  103. Manta, C. et al. CX(3)CR1+ macrophages support IL-22 production by innate lymphoid cells during infection with Citrobacter rodentium. Mucosal Immunol. 6, 177188 (2013).
  104. Aychek, T. et al. IL-23-mediated mononuclear phagocyte crosstalk protects mice from Citrobacter rodentium–induced colon immunopathology. Nat. Commun. 6, 6525 (2015).
  105. Satoh-Takayama, N. et al. The chemokine receptor CXCR6 controls the functional topography of interleukin-22 producing intestinal innate lymphoid cells. Immunity 41, 776788 (2014).
  106. Franchi, L. et al. NLRC4-driven production of IL-1β discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 13, 449456 (2012).
  107. Seo, S.U. et al. Distinct commensals induce interleukin-1β via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury. Immunity 42, 744755 (2015).
  108. van de Pavert, S.A. et al. Maternal retinoids control type 3 innate lymphoid cells and set the offspring immunity. Nature 508, 123127 (2014).
  109. Bartemes, K.R., Kephart, G.M., Fox, S.J. & Kita, H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J. Allergy Clin. Immunol. 134, 671678 (2014).
  110. Hams, E. et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc. Natl. Acad. Sci. USA 111, 367372 (2014).
  111. Chang, Y.J. et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat. Immunol. 12, 631638 (2011).
  112. Halim, T.Y., Krauss, R.H., Sun, A.C. & Takei, F. Lung natural helper cells are a critical source of TH2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 36, 451463 (2012).
  113. Bartemes, K.R. et al. IL-33-responsive lineage+CD25+CD44hi lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J. Immunol. 188, 15031513 (2012).
  114. Imai, Y. et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc. Natl. Acad. Sci. USA 110, 1392113926 (2013).
  115. Kabata, H. et al. Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. Nat. Commun. 4, 2675 (2013).
  116. Kim, B.S. et al. Basophils promote innate lymphoid cell responses in inflamed skin. J. Immunol. 193, 37173725 (2014).
  117. Motomura, Y. et al. Basophil-derived interleukin-4 controls the function of natural helper cells, a member of ILC2s, in lung inflammation. Immunity 40, 758771 (2014).
  118. Barnig, C. et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci. Transl. Med. 5, 74ra126 (2013).
  119. Halim, T.Y. et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 40, 425435 (2014).
  120. Oliphant, C.J. et al. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4+ T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity 41, 283295 (2014).
  121. Mirchandani, A.S. et al. Type 2 innate lymphoid cells drive CD4+ Th2 cell responses. J. Immunol. 192, 24422448 (2014).
  122. Villanova, F. et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J. Invest. Dermatol. 134, 984991 (2014).
  123. Kirchberger, S. et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 210, 917931 (2013).
  124. Kim, H.Y. et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat. Med. 20, 5461 (2014).
  125. Pantelyushin, S. et al. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 122, 22522256 (2012).
  126. Geremia, A. et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208, 11271133 (2011).
  127. Powell, N. et al. Interleukin-6 increases production of cytokines by colonic innate lymphoid cells in mice and patients with chronic intestinal inflammation. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2015.04.017 (2015).
  128. Ermann, J., Staton, T., Glickman, J.N., de Waal Malefyt, R. & Glimcher, L.H. Nod/Ripk2 signaling in dendritic cells activates IL-17A-secreting innate lymphoid cells and drives colitis in T-bet−/−Rag2−/− (TRUC) mice. Proc. Natl. Acad. Sci. USA 111, E2559E2566 (2014).
  129. Muñoz, M. et al. Interleukin-22 induces interleukin-18 expression from epithelial cells during intestinal infection. Immunity 42, 321331 (2015).
  130. Huber, S. et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491, 259263 (2012).
  131. Eisenring, M., vom Berg, J., Kristiansen, G., Saller, E. & Becher, B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat. Immunol. 11, 10301038 (2010).
  132. Nussbaum, J.C. et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 502, 245248 (2013).
  133. Lee, M.W. et al. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell 160, 7487 (2015).
  134. Brestoff, J.R. & Artis, D. Immune regulation of metabolic homeostasis in health and disease. Cell 161, 146160 (2015).
  135. Vasanthakumar, A. et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat. Immunol. 16, 276285 (2015).
  136. Burzyn, D. et al. A special population of regulatory T cells potentiates muscle repair. Cell 155, 12821295 (2013).
  137. Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564568 (2014).
  138. Klatt, N.R. et al. Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol. 5, 646657 (2012).
  139. Gray, E.E., Friend, S., Suzuki, K., Phan, T.G. & Cyster, J.G. Subcapsular sinus macrophage fragmentation and CD169+ bleb acquisition by closely associated IL-17-committed innate-like lymphocytes. PLoS ONE 7, e38258 (2012).
  140. Kim, C.J. et al. A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis. Mucosal Immunol. 5, 670680 (2012).
  141. Li, H. et al. Hypercytotoxicity and rapid loss of NKp44+ innate lymphoid cells during acute SIV infection. PLoS Pathog. 10, e1004551 (2014).
  142. Sonnenberg, G.F. et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 336, 13211325 (2012).
  143. Qiu, J. et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 39, 386399 (2013).
  144. Brenchley, J.M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 13651371 (2006).
  145. Guo, X. et al. Innate lymphoid cells control early colonization resistance against intestinal pathogens through ID2-dependent regulation of the microbiota. Immunity 42, 731743 (2015).
  146. Hepworth, M.R. & Sonnenberg, G.F. Regulation of the adaptive immune system by innate lymphoid cells. Curr. Opin. Immunol. 27, 7582 (2014).
  147. Mortha, A. et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 343, 1249288 (2014).
  148. Kruglov, A.A. et al. Nonredundant function of soluble LTα3 produced by innate lymphoid cells in intestinal homeostasis. Science 342, 12431246 (2013).
  149. Tsuji, M. et al. Requirement for lymphoid tissue-inducer cells in isolated follicle formation and T cell-independent immunoglobulin A generation in the gut. Immunity 29, 261271 (2008).
  150. Hepworth, M.R. et al. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature 498, 113117 (2013).
  151. Goto, Y. et al. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. Immunity 40, 594607 (2014).
  152. Hepworth, M.R. et al. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4+ T cells. Science (in the press, 2015).
  153. Perry, J.S. et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci. Transl. Med. 4, ra106 (2012).
  154. Papp, K.A. et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 11811189 (2012).
  155. Leonardi, C. et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366, 11901199 (2012).
  156. Genovese, M.C. et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62, 929939 (2010).
  157. Bowman, E.P., Chackerian, A.A. & Cua, D.J. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr. Opin. Infect. Dis. 19, 245252 (2006).
  158. Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 16931700 (2012).
  159. Targan, S.R. et al. Mo2083 A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease. Gastroenterology 143, e26 (2014).
  160. Kaser, A. Not all monoclonals are created equal: lessons from failed drug trials in Crohn's disease. Best Pract. Res. Clin. Gastroenterol. 28, 437449 (2014).
  161. Colombel, J.F., Sendid, B., Jouault, T. & Poulain, D. Secukinumab failure in Crohn's disease: the yeast connection? Gut 62, 800801 (2013).

Download references

Author information

Affiliations

  1. Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA.

    • Gregory F Sonnenberg &
    • David Artis
  2. Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York, USA.

    • Gregory F Sonnenberg &
    • David Artis
  3. The Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medical College, New York, New York, USA.

    • Gregory F Sonnenberg &
    • David Artis

Competing financial interests

David Artis is a scientific advisor for Bio-Techne and Second Genome, although these programs are not referred to herein.

Corresponding author

Correspondence to:

Author details

Additional data